MDT

96.14

+0.32%↑

VEEV

285.46

-0.39%↓

A

136.96

-1.69%↓

HQY

93.74

+1.62%↑

PHR.US

22.45

+1.77%↑

MDT

96.14

+0.32%↑

VEEV

285.46

-0.39%↓

A

136.96

-1.69%↓

HQY

93.74

+1.62%↑

PHR.US

22.45

+1.77%↑

MDT

96.14

+0.32%↑

VEEV

285.46

-0.39%↓

A

136.96

-1.69%↓

HQY

93.74

+1.62%↑

PHR.US

22.45

+1.77%↑

MDT

96.14

+0.32%↑

VEEV

285.46

-0.39%↓

A

136.96

-1.69%↓

HQY

93.74

+1.62%↑

PHR.US

22.45

+1.77%↑

MDT

96.14

+0.32%↑

VEEV

285.46

-0.39%↓

A

136.96

-1.69%↓

HQY

93.74

+1.62%↑

PHR.US

22.45

+1.77%↑

Search

Bio-Techne Corp

Aperta

SettoreSettore sanitario

58.81 -0.89

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

58.08

Massimo

59.73

Metriche Chiave

By Trading Economics

Entrata

-40M

-18M

Vendite

783K

317M

P/E

Media del settore

134.609

37.257

EPS

0.53

Rendimento da dividendi

0.51

Margine di Profitto

-5.577

Dipendenti

3,100

EBITDA

-61M

6.4M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+13.45% upside

Dividendi

By Dow Jones

Rendimento da dividendi

Media del settore

0.51%

2.94%

Utili prossimi

29 ott 2025

Prossima data del Dividendo

21 nov 2025

Prossima data del' Ex Dividendo

10 nov 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

750M

9.6B

Apertura precedente

59.7

Chiusura precedente

58.81

Notizie sul Sentiment di mercato

By Acuity

15%

85%

19 / 371 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Weak Bullish Evidence

Bio-Techne Corp Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

13 ott 2025, 21:45 UTC

Acquisizioni, Fusioni, Takeovers

Goldman Sachs to Acquire Industry Ventures for Up to $965 Million -- Update

13 ott 2025, 21:07 UTC

Acquisizioni, Fusioni, Takeovers

Goldman Sachs to Acquire Industry Ventures for Up to $965 Million

13 ott 2025, 17:03 UTC

I principali Market Mover

Canaan ADRs Climb on Launch of Gas-to-Computing Pilot in Canada

13 ott 2025, 23:53 UTC

Discorsi di Mercato

Gold Rises, Buoyed by Bullish Fundamental Backdrop -- Market Talk

13 ott 2025, 23:39 UTC

Discorsi di Mercato

Nikkei May Rise, Tracking Wall Street's Gains -- Market Talk

13 ott 2025, 22:15 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

13 ott 2025, 22:15 UTC

Discorsi di Mercato

Precinct Properties NZ's Equity Raising Looks Opportunistic -- Market Talk

13 ott 2025, 21:57 UTC

Acquisizioni, Fusioni, Takeovers

Goldman Buys $7B Venture-Capital Firm in Latest Asset-Management Bet -- Barrons.com

13 ott 2025, 21:36 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

13 ott 2025, 21:36 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

13 ott 2025, 21:36 UTC

Discorsi di Mercato

Fletcher's Near-Term Headwinds Don't Cloud Earnings Opportunity -- Market Talk

13 ott 2025, 21:30 UTC

Acquisizioni, Fusioni, Takeovers

Goldman Sachs to Acquire Industry Ventures for Up to $965M -- Update

13 ott 2025, 21:06 UTC

Acquisizioni, Fusioni, Takeovers

Goldman Buys $7B Venture-Capital Firm in Latest Asset-Management Bet -- Barrons.com

13 ott 2025, 20:52 UTC

Acquisizioni, Fusioni, Takeovers

Goldman Sachs to Acquire Industry Ventures for Up to $965M

13 ott 2025, 20:50 UTC

Discorsi di Mercato

Tech, Media & Telecom Roundup: Market Talk

13 ott 2025, 20:35 UTC

Acquisizioni, Fusioni, Takeovers

Goldman Expects to Close Deal in 1Q

13 ott 2025, 20:34 UTC

Acquisizioni, Fusioni, Takeovers

Industry Ventures Will Be Part of Goldman's External Manager Platform, External Investing Group

13 ott 2025, 20:33 UTC

Acquisizioni, Fusioni, Takeovers

Industry Ventures Currently Manages $7B of Assets Under Supervision

13 ott 2025, 20:32 UTC

Acquisizioni, Fusioni, Takeovers

Goldman Sachs: Deal to Include Up to $300M of Additional Contingent Consideration Based on Future Performance Through 2030

13 ott 2025, 20:31 UTC

Acquisizioni, Fusioni, Takeovers

Goldman Sachs: Consideration to Include $665M Cash and Equity Payable at Closing

13 ott 2025, 20:29 UTC

Acquisizioni, Fusioni, Takeovers

Goldman Sachs to Buy VC Firm Industry Ventures

13 ott 2025, 19:05 UTC

Discorsi di Mercato

Oil Futures Pick Up on Easing U.S.-China Tension -- Market Talk

13 ott 2025, 18:59 UTC

Discorsi di Mercato

U.S. Natural Gas Futures Snap Losing Streak -- Market Talk

13 ott 2025, 18:26 UTC

Discorsi di Mercato

Precious Metals Close at New Record Highs -- Market Talk

13 ott 2025, 18:10 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

13 ott 2025, 18:10 UTC

Discorsi di Mercato

Broadcom's OpenAI Deal Highlights AI Opportunity -- Market Talk

13 ott 2025, 17:05 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

13 ott 2025, 17:05 UTC

Discorsi di Mercato

OpenAI Deal Offers Huge Upside to Broadcom's Earnings -- Market Talk

13 ott 2025, 16:03 UTC

Acquisizioni, Fusioni, Takeovers

Umicore Completes Sale, Subsequent Lease-in of Permanent Gold Inventories

13 ott 2025, 15:35 UTC

Discorsi di Mercato

Precious Metals Push Record Highs Further -- Market Talk

Confronto tra pari

Modifica del prezzo

Bio-Techne Corp Previsione

Obiettivo di Prezzo

By TipRanks

13.45% in crescita

Previsioni per 12 mesi

Media 66.55 USD  13.45%

Alto 75 USD

Basso 53 USD

Basato su 14 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Bio-Techne Corp - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

14 ratings

11

Acquista

3

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

49.67 / 50.24Supporto e resistenza

A breve termine

Weak Bullish Evidence

A termine intermedio

Weak Bullish Evidence

A lungo termine

Strong Bearish Evidence

Sentiment

By Acuity

19 / 371 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove rialziste molto forti

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Bio-Techne Corp

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company has strategic partnership with ALZpath, Inc. to accelerate breakthroughs in neurodegenerative disease research and treatment, including Alzheimer's disease. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
help-icon Live chat